Impact of Tildrakizumab on Patient Reported Outcomes in Patients With Moderate-to-severe Psoriasis in Canada

Recruiting

TildrakizumabImpact of Tildrakizumab on Patient Reported Outcomes in Patients With Moderate-to-severe Psoriasis in Canada

Sponsor:

Chronicle Academy

Code:

NCT07370766

Conditions

Psoriasis (PsO)

Moderate to Severe Psoriasis

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-02-02. This information was provided to ClinicalTrials.gov by Chronicle Academy on 2026-01-27.